Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06117293
Other study ID # LMI22001
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date February 21, 2023
Est. completion date September 1, 2025

Study information

Verified date November 2023
Source LUTRONIC Corporation
Contact Alexander Denis
Phone 9788959206
Email adenis@lutronic.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Evaluate the Safety and Efficacy of the Mosaic Ultra 1550nm system for the treatment of skin tone and texture, facial rejuvenation, photoaging, wrinkles, scars, stretch marks, acne vulgaris and hair loss.


Recruitment information / eligibility

Status Recruiting
Enrollment 200
Est. completion date September 1, 2025
Est. primary completion date September 1, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: - Non-smoking, Male or Female - Age 18 - 60 years old - Understands and accepts the obligation not to undergo any other procedures in the areas to be treated. - Participants who are willing and able to comply with all study participation requirements including returning for follow-up visits and abstaining from exclusionary procedures for the duration of the study. - OPTIONAL - Participants who are willing to undergo biopsies. Exclusion Criteria: - Previous surgical or cosmetic procedure to the target area in the last 6 to 12 months that could interfere with the treatment procedure - A study participant must not be pregnant or have been pregnant in the last 3 months - A recent history of smoking (6 months) - Presence of an active skin disease or condition that may affect wound healing (ie. diabetes myelitis; connective tissue disease; radiation therapy; or chemotherapy) - Seizure disorder caused by bright light - A history of thrombophlebitis - A history of acute infections - A history of heart failure - Cancer, malignant disease, skin pathology, condition, or allergic reactions that could interfere with evaluation or with the use of typical ancillary medical treatments or care used before, during, or after treatments - Received or is anticipated to receive antiplatelets, anticoagulants, thrombolytics, vitamin E, or anti-inflammatories within 2 weeks prior to treatment - Intolerance or allergy to medications that could be prescribed before or after the procedure (eg, antibiotics, anesthesia) - A history of keloids - A history or evidence of poor wound healing - A history of coagulative disorder or current use of anticoagulant drugs within 2 weeks of study participation - Use of steroids within 2 weeks of study treatments - Patients with implanted pacemaker or defibrillator, or metal pins, or prosthetic joints within 4 cm of treatment area - History of psychoneurosis and/or a history of alcohol or drug abuse

Study Design


Intervention

Device:
Mosaic
1550 Fractional Laser System

Locations

Country Name City State
United States Lutronic Billerica Massachusetts
United States Advanced Dermatology Lincolnshire Illinois
United States Dermatology & Skin Health Peabody Massachusetts

Sponsors (1)

Lead Sponsor Collaborator
LUTRONIC Corporation

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Photographic Assessment Evaluation of Randomized Before Treatment and 3-Month Follow-Up Images by Blinded Evaluators 90-day Follow-Up
Secondary Safety Assessment Evaluation of Adverse Events up to 90 days post final treatment
Secondary Subject Satisfaction Scoring of Satisfaction from Extremely Satisfied to Extremely Dissatisfied 30-day and 90-day Follow-Up
Secondary Physician Satisfaction Scoring of Satisfaction from Extremely Satisfied to Extremely Dissatisfied 30-day and 90-day Follow-Up
Secondary Subject Clinical Global Aesthetic Improvement Scale Scoring on the Clinical Global Aesthetic Improvement Scale is completed by having the subject select one option from the scale corresponding to their perspective of the improvement seen in their treated conditions.
Response options are 1 - Very Much Improved, 2 - Much Improved, 3 - Improved, 4 - No Change, and 5 - Worsened. A response of 1 - Very Much Improved is the best outcome while a score of 5 - Worsened is the worse outcome.
30-day and 90-day Follow-Up
Secondary Physician Clinical Global Aesthetic Improvement Scale Scoring on the Clinical Global Aesthetic Improvement Scale is completed by having the physician select one option from the scale corresponding to their perspective of the improvement seen in their treated conditions of the subject.
Response options are 1 - Very Much Improved, 2 - Much Improved, 3 - Improved, 4 - No Change, and 5 - Worsened. A response of 1 - Very Much Improved is the best outcome while a score of 5 - Worsened is the worse outcome.
30-day and 90-day Follow-Up
Secondary Coagulation Zone Measurements Biopsies taken from healthy tissue prior to treatment up to 21 days post treatment to evaluate histological effect of the device. Tissue samples will be evaluated and the depth and width of the coagulation zones due to the laser (measures in micrometers) Baseline, Immediate Post Treatment, 4 Days Post, 14 Days Post, 21 Days Post
Secondary Epidermal Inflammatory Response Biopsies taken from healthy tissue prior to treatment up to 21 days post treatment to evaluate histological effect of the device. Tissue samples will be reviewed for markers of inflammation and coagulation in the epidermis. General comments and observations of the tissue will be completed by a pathologist. Baseline, Immediate Post Treatment, 4 Days Post, 14 Days Post, 21 Days Post
Secondary Dermal Inflammatory Response Biopsies taken from healthy tissue prior to treatment up to 21 days post treatment to evaluate histological effect of the device. Tissue samples will be reviewed for markers of inflammation and coagulation in the dermis. General comments and observations of the tissue will be completed by a pathologist. Baseline, Immediate Post Treatment, 4 Days Post, 14 Days Post, 21 Days Post
Secondary Tissue Reepithelization Biopsies taken from healthy tissue prior to treatment up to 21 days post treatment to evaluate histological effect of the device. Tissue samples will be evaluated to determine the timepoint in which there is a reepithelization of the treated tissue. Timepoint of reepithelization will be determined by a pathologist reviewing the imaging. Baseline, Immediate Post Treatment, 4 Days Post, 14 Days Post, 21 Days Post
See also
  Status Clinical Trial Phase
Completed NCT04321070 - Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris Phase 1
Recruiting NCT05755256 - The Impact of Probiotics on Skin Hydration in Youth With Mild Acne Phase 2
Completed NCT05131373 - Safety, Tolerability, and Immunogenicity of ORI-A-ce001 for the Treatment of Acne Vulgaris Phase 1
Completed NCT01445301 - Study STF115287, a Clinical Confirmation Study of GSK2585823 in the Treatment of Acne Vulgaris in Japanese Subjects Phase 3
Completed NCT03303170 - Non-Significant Risk Study of Sebacia Microparticles in the Treatment of Facial Acne Vulgaris N/A
Completed NCT04698239 - Clinical Evaluation of the Safety and Benefits of the Milesman 445 nm Blue Laser on Inflammatory Acne Lesions. N/A
Completed NCT02886715 - A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris Phase 3
Terminated NCT02924428 - Venus Versa Diamondpolar Applicator Treatment Followed by AC Dual Applicator Treatment for Facial Acne Vulgaris N/A
Not yet recruiting NCT02491060 - A Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris Phase 3
Not yet recruiting NCT02525822 - Study to Compare the Safety and Efficacy of IDP-123 Lotion to Tazorac Cream in the Treatment of Acne Vulgaris Phase 2
Completed NCT02709902 - Study Comparing Adapalene/BP Gel to EPIDUO® FORTE and Both to a Placebo Control in Treatment of Acne Vulgaris Phase 1
Not yet recruiting NCT02535871 - A Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris Phase 3
Completed NCT02913001 - The Effect of a Low Glycemic Load Diet on Hormonal Markers Associated With Acne N/A
Completed NCT02250430 - A Phase 1 Study Assessing Local Cutaneous Effects of SB204 Phase 1
Completed NCT01769664 - A Study Comparing Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel to Duac® Topical Gel in the Treatment of Acne Vulgaris Phase 1
Completed NCT01694810 - Cutaneous Tolerability and Safety of NVN1000 Topical Gel in Healthy Volunteers Phase 1
Completed NCT01727440 - Identifying the Genetic Predictors of Severe Acne Vulgaris and the Outcome of Oral Isotretinoin Treatment N/A
Completed NCT01194375 - A Dose-Ranging Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris Phase 2
Completed NCT01706250 - U0289-401: Eight Week, Split-face, Study to Determine and Compare the Efficacy and Tolerability of MAXCLARITY™ II to PROACTIV™ Phase 4
Completed NCT02524665 - 8 Week Study to Evaluate and Compare the Efficacy and Tolerability of MAXCLARITY II and MURAD To Treat Acne Phase 4